A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 677-681

  Lindley, Steven E ^a,b   Carlson, Eve B ^b,c   Hill, Kimberly ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c National Center for PTSD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

ABNORMAL DREAMING; ADULT; ADVERSE OUTCOME; ANXIETY; ARTICLE; ATAXIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; FATIGUE; HUMAN; MALE; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PARESTHESIA; PATHOLOGICAL LAUGHTER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SIDE EFFECT; SYMPTOM; URINARY TRACT INFECTION; VERTIGO; VETERAN; VISUAL ILLUSION; AGE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; HOSPITALIZATION; MIDDLE AGED; PATIENT; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RASH; STATISTICS; TIME; TREATMENT OUTCOME;

AGE FACTORS; ANTICONVULSANTS; CHRONIC DISEASE; COMBAT DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VETERANS;

EID: 39649093687     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31815a43ee     Document Type: Article

References (25)

1. Breslau N, Kessler RC, Chilcoat HD, et al. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch Gen Psychiatry. 1998;55(7):626-632.
2. Kulka RA, Schlenger WE, Fairbank JA, et al. Contractual Report of Findings from the National Vietnam Veterans Readjustment Study: Clinical Interview Questionnaires. Research Triangle Park, NC: Research Triangle Institute; 1988.
3. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry. 2001;158(8):1184-1190.
4. Friedman MJ, Schnurr PP, McDonagh-Coyle A. Post-traumatic stress disorder in the military veteran. Psychiatr Clin North Am. 1994;17(2): 265-277.
5. Bollinger AR, Riggs DS, Blake DD, et al. Prevalence of personality disorders among combat veterans with posttraumatic stress disorder. J Trauma Stress. 2000;13(2):255-270.
6. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006;1:CD002795.
7. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63(3):199-206.
8. Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur Neuropsychopharmacol. 2006;16(5):340-349.
9. Albucher RC, Liberzon I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res. 2002;36(6):355-367.
10. Ford N. The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J Trauma Stress. 1996;9(4):857-863.
11. Looff D, Grimley P, Kuller F, et al. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry. 1995;34(6):703-704.
12. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991;52(9):361-364.
13. Lipper S, Davidson JR, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986; 27(12):849-854.
14. Clark RD, Canive JM, Calais LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999;12(2): 395-401.
15. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry. 1991;148(8):1086-1087.
16. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63(1):15-20.
17. Hamner M, Brodrick P, Lobbate L. Gabapentin in PTSD: a retrospective, clinical series of adjuctive therapy. Ann Clin Psychiatry. 2001;13(3):141-146.
18. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder [in process citation]. Biol Psychiatry. 1999;45(9):1226-1229.
19. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry. 2003;64(suppl 8):5-8.
20. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3-S9.
21. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004;4(21):24.
22. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.
23. Guy W, ed. Assessment Manual for Psychopharmacology. Washington, DC: National Institue of Mental Health, US Department of Health, Education, and Welfare; 1976.
24. Beck A, Steer R. Beck Depression Inventory Manual. San Antonio: The Psychological Corporation; 1987.
25. Carlson EB, Waelde LC. Preliminary psychometric properties of the Traumatic Dissociation Scale. In: Annual Meeting of the International Society for Traumatic Stress Studies. San Antonio, 2000.